Novartis to Acquire The Medicines Company for $9.7B

 Novartis to Acquire The Medicines Company for $9.7B

Novartis to Acquire The Medicines Company for $9.7B

Shots:

  • Novartis to acquire The Medicine Company in all-cash transaction for $85/share at a 24% 1-day premium, making fully diluted equity value as $7.7B and a total deal value as $9.7B. The transaction is expected to be closed in Q1’20  
  • The acquisition will expand Novartis’ global footprints with the addition of Inclisiran in cardiovascular portfolio, thus enable Novartis to leverage its commercial capabilities globally
  • The Medicine Company’s Inclisiran is first-in-class siRNA inhibitor targeting PCSK9, currently being evaluated in P-III (ORION-9, 10 and 11) studies for patients with atherosclerotic cardiovascular disease (ASCVD) or familial hypercholesterolemia (FH), demonstrating potent and durable LDL-C reduction with its expected regulatory submission in the US in Q4’19 and in the EU in Q1’20

Click here to­ read full press release/ article | Ref: Novartis  | Image: Chemistry World

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post